Sensei Biotherapeutics stockholders approve change of control and 24x share authorization increase

Filed June 10, 2026 · Period ending June 10, 2026 · ~1 min read

Key Changes

• high

  Stockholders approved conversion of Series B Preferred Stock that will trigger a change of control under Nasdaq rules, meaning existing common shareholders will be significantly diluted and control shifts to preferred holders.

  Item 5.07: Annual Meeting verify on EDGAR →
• high

  Authorized common stock increased from 12.5 million to 300 million shares (24x expansion), providing capacity for the preferred conversion and future capital raises but creating massive dilution potential.

  Item 5.03: Charter Amendment verify on EDGAR →
• high

  New 2026 Equity Incentive Plan approved with 2.7 million shares initially reserved, plus automatic annual increases of 5% of outstanding shares each January through 2036 for employee compensation.

  Item 5.02: Equity Plans verify on EDGAR →